scPharmaceuticals (NASDAQ:SCPH) Earns “Buy” Rating from HC Wainwright

scPharmaceuticals (NASDAQ:SCPH)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 427.86% from the company’s current price.

Separately, Craig Hallum dropped their price objective on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday.

scPharmaceuticals Stock Performance

Shares of scPharmaceuticals stock traded down $0.50 during trading on Thursday, reaching $3.41. The company’s stock had a trading volume of 2,961,492 shares, compared to its average volume of 259,608. The company has a 50-day moving average price of $4.53 and a two-hundred day moving average price of $4.50. The firm has a market cap of $170.60 million, a PE ratio of -2.19 and a beta of 0.15. scPharmaceuticals has a fifty-two week low of $3.24 and a fifty-two week high of $6.71. The company has a current ratio of 4.84, a quick ratio of 3.66 and a debt-to-equity ratio of 4.32.

scPharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). The company had revenue of $8.05 million for the quarter, compared to analysts’ expectations of $8.04 million. scPharmaceuticals had a negative net margin of 252.18% and a negative return on equity of 201.84%. On average, analysts forecast that scPharmaceuticals will post -1.34 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SCPH. BNP Paribas Financial Markets raised its stake in scPharmaceuticals by 116.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after purchasing an additional 3,101 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in scPharmaceuticals in the 3rd quarter valued at about $57,000. MetLife Investment Management LLC increased its stake in shares of scPharmaceuticals by 135.0% during the 3rd quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock valued at $77,000 after acquiring an additional 9,752 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of scPharmaceuticals by 32.2% during the 3rd quarter. Captrust Financial Advisors now owns 18,539 shares of the company’s stock valued at $85,000 after acquiring an additional 4,513 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of scPharmaceuticals during the 1st quarter valued at about $90,000. Institutional investors and hedge funds own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.